The actual design and construction of an oral film capable of effective therapeutic delivery can be challenging and requires the creation of new technologies. As a result of these innovations, buccal films are now a commercially viable dosage form that can solve many problems faced by the pharmaceutical industry, patients, and their caregivers, according to CURE Pharmaceutical’s CEO Rob Davidson and its COO Jessica Rousset.

Oral films will be able to replace daily injections, such as apomorphine shots taken by patients suffering from Parkinson’s disease. They can improve the bioavailability of drugs, such as cannabinoids, potentially lowering their dose and psychoactive side effects. When rapid symptom relief is needed, they can deliver a bolus effect. They are a convenient alternative to unpalatable liquids for children and hard-to-swallow pills for the elderly.

“CURE Pharmaceutical’s approach to buccal film development with CUREfilm leverages the inevitable salivary flush of a single layer film to create better drug-release profiles,” said Davidson and Rousset. “We design our products to combine the fast onset bolus effect of buccal delivery with the extended release of GI delivery to achieve an overall pulsatileor sustained-release profile. Indeed, with buccal delivery, blood levels can peak quickly, and a shorter half-life can mean the effect wears off rapidly.”

Read the full article: BUCCAL FILMS – Better Drug Release & Patient Experiences With Buccal Films (Drug Development & Delivery)